AFFY (Affymax) Cyclically Adjusted PB Ratio: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Affymax Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Affymax  (OTCPK:AFFY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Affymax Cyclically Adjusted PB Ratio Related Terms


Affymax Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Affymax's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affymax Cyclically Adjusted PB Ratio Chart

Affymax Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Affymax Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AFFY vs APOP, ONTX, BTHE: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Affymax's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Affymax's Cyclically Adjusted PB Ratio falls into.



Affymax Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Affymax's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2014 is calculated as:

For example, Affymax's adjusted Book Value per Share data for the three months ended in Jun. 2014 was:

Adj_Book=Book Value per Share/CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=0.138/238.3430*238.3430
=0.138

Current CPI (Jun. 2014) = 238.3430.

Affymax Quarterly Data

Book Value per Share CPI Adj_Book
200409 0.000 189.900 0.000
200412 -5.858 190.300 -7.337
200503 0.000 193.300 0.000
200506 0.000 194.500 0.000
200509 0.000 198.800 0.000
200512 -7.641 196.800 -9.254
200603 -8.175 199.800 -9.752
200606 -8.433 202.900 -9.906
200609 -8.769 202.900 -10.301
200612 7.857 201.800 9.280
200703 7.491 205.352 8.694
200706 6.990 208.352 7.996
200709 6.266 208.490 7.163
200712 5.559 210.036 6.308
200803 4.661 213.528 5.203
200806 3.635 218.815 3.959
200809 2.100 218.783 2.288
200812 0.478 210.228 0.542
200903 1.680 212.709 1.882
200906 0.664 215.693 0.734
200909 -0.143 215.969 -0.158
200912 2.803 215.949 3.094
201003 2.587 217.631 2.833
201006 3.453 217.965 3.776
201009 2.960 218.439 3.230
201012 2.850 219.179 3.099
201103 3.402 223.467 3.628
201106 3.120 225.722 3.294
201109 2.888 226.889 3.034
201112 2.127 225.672 2.246
201203 3.129 229.392 3.251
201206 2.326 229.478 2.416
201209 1.777 231.407 1.830
201212 0.222 229.601 0.230
201303 -0.394 232.773 -0.403
201306 0.009 233.504 0.009
201309 -0.023 234.149 -0.023
201312 -0.038 233.049 -0.039
201403 -0.062 236.293 -0.063
201406 0.138 238.343 0.138

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Affymax Business Description

Address 630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.